EX-10.58 14 dex1058.htm EXIT FEE AGREEMENT EXIT FEE AGREEMENTExit Fee Agreement • May 5th, 2020 • New York
THIS EXIT FEE AGREEMENT (this “Agreement”) is made as of May 27, 2005, by and between DIGITAL LAKESIDE, LLC, a Delaware limited liability company having an address at 560 Mission Street, Suite 2900, San Francisco, California 94105 (“Borrower”) and MORGAN STANLEY MORTGAGE CAPITAL INC., a New York corporation, having an address at 1221 Avenue of the Americas, 27th Floor, New York, New York 10020 (“Lender”).
Exit Fee AgreementExit Fee Agreement • January 6th, 2020 • Alimera Sciences Inc • Pharmaceutical preparations • New York
Reference is made to the Loan and Security Agreement, dated as of December 31, 2019 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and among Solar Capital Ltd., a Maryland corporation (“Solar”), as collateral agent (in such capacity, “Agent”), the lenders party thereto from time to time including Solar in its capacity as a lender (each a “Lender” and collectively, the “Lenders”), and Alimera Sciences, Inc., a Delaware corporation (“Borrower”). As a condition precedent to the Lenders’ entry into the Loan Agreement, the Lenders require that Borrower agree to pay to the Lenders a fee upon the occurrence of certain events, as described in this Exit Fee Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Exit Fee Agreement”), dated as of December 31, 2019 (the “Effective Date”), by and among Solar as Agent, the Lenders and Borrower. Capitalized terms used herein and not ot
Exit Fee AgreementExit Fee Agreement • May 5th, 2022 • Ardelyx, Inc. • Pharmaceutical preparations • New York
Reference is made to the Loan and Security Agreement, dated as of February 23, 2022 (as may be amended, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and among SLR Investment Corp., a Maryland corporation (“SLR”), as collateral agent (in such capacity, “Agent”), the lenders party thereto from time to time including SLR in its capacity as a lender (each a “Lender” and collectively, the “Lenders”), and ARDELYX, INC., a Delaware corporation (“Borrower”). As a condition precedent to the Lenders’ entry into the Loan Agreement, the Lenders require that Borrower agree to pay to the Lenders a fee upon the occurrence of certain events as described in this Exit Fee Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Exit Fee Agreement”), dated as of the date hereof (the “Effective Date”), by and among SLR, as Agent, the Lenders and Borrower. Capitalized terms used herein and not otherwise
Exit Fee AgreementExit Fee Agreement • April 19th, 2021 • Rezolute, Inc. • Pharmaceutical preparations • New York
Reference is made to the Loan and Security Agreement, dated as of April 14, 2021 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), by and among SLR Investment Corp., a Maryland corporation (“SLR”), as collateral agent (in such capacity, “Agent”), the lenders party thereto from time to time including SLR in its capacity as a lender (each a “Lender” and collectively, the “Lenders”), and Rezolute, Inc., a Delaware corporation (“Borrower”). As a condition precedent to the Lenders’ entry into the Loan Agreement, the Lenders require that Borrower agree to pay to the Lenders a fee upon the occurrence of certain events, as described in this Exit Fee Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Exit Fee Agreement”), dated as of April 14, 2021 (the “Effective Date”), by and among SLR as Agent, the Lenders and Borrower. Capitalized terms used herein and not otherwise defined h
Exit Fee AgreementExit Fee Agreement • August 7th, 2018 • Ardelyx, Inc. • Pharmaceutical preparations • New York
This agreement (as the same may be amended, restated, modified, or supplemented from time to time, this “Exit Fee Agreement”), dated as of May 16, 2018 (the “Effective Date”), is by and among Ardelyx, Inc., a Delaware corporation (“Borrower”), Solar Capital Ltd., a Maryland corporation (“Solar”), and Western Alliance Bank, an Arizona corporation (“Western Alliance Bank”).
Exit Fee AgreementExit Fee Agreement • January 8th, 2018 • Alimera Sciences Inc • Pharmaceutical preparations • New York
Reference is made to the Loan and Security Agreement, dated as of January 5, 2018 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and among Solar Capital Ltd., a Maryland corporation (“Solar”), as collateral agent (in such capacity, “Agent”), the lenders party thereto from time to time including Solar in its capacity as a lender (each a “Lender” and collectively, the “Lenders”), and Alimera Sciences, Inc., a Delaware corporation (“Borrower”). As a condition precedent to the Lenders’ entry into the Loan Agreement, the Lenders require that Borrower agree to pay to the Lenders a fee upon the occurrence of certain events, as described in this Exit Fee Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Exit Fee Agreement”), dated as of January 5, 2018 (the “Effective Date”), by and among Solar as Agent, the Lenders and Borrower. Capitalized terms used herein and not otherw
